FGFR4 and alveolar rhabdomyosarcoma: Guadecitabine (SGI-110), a next-generation DNA methyltransferase inhibitor (DNMTi), reduces H3K4 mono-methylation across the FGFR4 super-enhancer in ARMS cells, leading to diminished FGFR4 transcription.